Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A scoping review of alopecia areata and its relationship to COVID-19 vaccinations.
Arch Dermatol Res
December 2024
Albert Einstein College of Medicine, Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.
In response to the COVID-19 pandemic several vaccines were produced, including novel mRNA and viral vector-based vaccines. Though COVID-19 had its own associated dermatological sequelae, the vaccines were associated with a new set of cutaneous side effects, including hypersensitivity reactions, vasculitis, and autoimmune-mediated reactions. Notably, alopecia areata (AA) was reported in several patients closely following a COVID-19 vaccine, especially in those with a personal or family history of AA.
View Article and Find Full Text PDFII Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata.
An Bras Dermatol
December 2024
Department of Internal Medicine, Universidade Federal do Paraná, Curitiba, PR, Brazil.
Background: Alopecia areata is a highly frequent disease with great variability in clinical presentation, severity, and prognosis. It has a significant negative impact on quality of life, especially in the moderate and severe forms.
Objective: To disseminate guidelines, prepared by a group of Brazilian experts, for the treatment and follow-up of patients with alopecia areata.
Clinical effectiveness and safety of Camrelizumab immunotherapy in treating advanced esophageal carcinoma.
Am J Transl Res
October 2024
Xiangya School of Pharmaceutical Sciences, Central South University Changsha 410013, Hunan, China.
Objective: To analyze the clinical effectiveness and safety of Camrelizumab immunotherapy in patients with advanced esophageal carcinoma (aEC).
Methods: A retrospective study was conducted on 142 aEC cases admitted between May 2020 to October 2022. The patients who received albumin-bound paclitaxel (ALB-bound PTX) and cis-platinum (DDP) were grouped into the control group (n=72), and the others received Camrelizumab immunotherapy in combination with ALB-bound PTX and DDP were grouped in to the research group (n=72).
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma.
BMC Cancer
November 2024
Department of Dermatology, University of Kiel, Kiel, Germany.
Background: Following the pivotal phase II trial BOLT, the Hedgehog (Hh) inhibitor sonidegib was approved in the EU to treat locally advanced basal cell carcinoma (laBCC) in patients not amenable to surgery or radiotherapy. We report safety data from the interim analysis of the real-world NISSO study.
Methods: NISSO is an ongoing non-interventional, multinational, post-authorization safety study (NCT04066504).
Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution.
Cancers (Basel)
October 2024
Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
Article Synopsis
- Advanced melanoma treatments have evolved with targeted therapies and immunotherapies, which significantly impact management but also lead to increased skin toxicities during treatment.
- A study in Bologna identified that 37.5% of 202 patients treated for melanoma developed cutaneous adverse events, primarily linked to drugs like ipilimumab and nivolumab.
- Most skin reactions were low-grade and manageable, but some resulted in severe conditions, highlighting the importance of recognizing and treating these toxicities to ensure patient quality of life.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!